Quantitative structure-activity relationship analysis of thiazolidineones: potent antidiabetic compounds

References

1. Centers for Disease Control and Prevention. National Diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. Atlanta, GA: Department of Health and Human Services. Centers for Disease Control and Prevention, 2008.Suche in Google Scholar

2. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care J 2007;30(Suppl 1):S4­–41.10.2337/dc07-S004Suche in Google Scholar PubMed

3. Prashant S, Kamlesh K, Gaurav K, Gopal KM. Efficient one-pot four-component synthesis of fused thiazolopyridin-2-ones in ionic liquid. J Chem Sci 2012, in press.Suche in Google Scholar

4. Prashant S, Kamlesh K, Monica D, Vijay KV, Narendera DP, Ramesh C, et al. Ionic liquid catalyzed synthesis of 7-phenyl-1,4,6,7-tetrahydro-thiazolo[5,4-d] pyrimidine-2,5-diones. C R Chimie 2012;15:504–10.10.1016/j.crci.2012.04.002Suche in Google Scholar

5. Kamlesh K, Prashant S, Monica D, Narendera DP, Ramesh C, Gopal KM. A catalyst free convenient one pot synthesis of multisubstituted chromeno-thiazolones. C R Chimie 2012;15:267–72.10.1016/j.crci.2011.12.004Suche in Google Scholar

6. Prashant S, Kamlesh K, Vartika T, Mohd S, Rajan P, Gopal KM, et al. A novel method to chemically bind the thiazolidine-2,4-dione through cross linked chitosan nanoparticles using malanodialdehyde as a cross linker. Can J Chem 2011;89:1–11.Suche in Google Scholar

7. Pradip K, Prankaj K, Jagvir S, Prashant S, Ramesh C. Synthesis and evaluation of antimicrobial activity of 8-phenyl-3,4,7,8-tetrahydrobisthiazolopyridine-2,6-dione derivatives. J Chem Asia 2011;2:101–14.Suche in Google Scholar

8. Prashant S, Pradeep K, Anju K, Rashmi K, Sujata KD, Satya P, et al. Synthesis and electrochemical studies of charge transfer complexes of thiazolidine-2, 4-dione with sigma and pi acceptors. Spectrochim Acta A Mol Biomol Spectrosc 2010;75:983–91.10.1016/j.saa.2009.12.019Suche in Google Scholar PubMed

9. Prashant S, Kamlesh K, Anju K, Rashmi K, Ramesh C. Copper nanoparticles in ionic liquid: an easy and efficient catalyst for selective Cara-Michael addition reaction. Catal Lett 2009;127:119–25.10.1007/s10562-008-9654-7Suche in Google Scholar

10. Prashant S, Kamlesh K, Anju K, Rashmi K, Ramesh C. Cu nanoparticles in ionic liquid: an easy and efficient catalyst for addition-elimination reaction between active methylene compounds and imines in an ionic liquid. Catal Lett 2009;130:648–54.10.1007/s10562-009-9944-8Suche in Google Scholar

11. Prashant S, Anju K, Rashmi K, Ramesh C. Copper nanoparticles in ionic liquid: an easy and efficient catalyst for the coupling of thiazolidine-2,4-dione, aromatic aldehyde and ammonium acetate. Catal Commun 2008;9:1618–23.10.1016/j.catcom.2008.01.010Suche in Google Scholar

12. Prashant S, Anju K, Rashmi K, Ramesh C. Copper nanoparticles in an ionic liquid: an efficient catalyst for the synthesis of bis-(4-hydroxy-2-oxothiazolyl)methanes. Tetrahedron Lett 2008;49:727–30.10.1016/j.tetlet.2007.11.106Suche in Google Scholar

13. Ajeet K, Prashant S, Amit S, Arnab D, Ramesh C, Subho M. Nano-sized copper as an efficient catalyst for one pot three component synthesis of thiazolidine-2, 4-dione derivatives. Catal Commun 2008;10:17–22.10.1016/j.catcom.2008.07.030Suche in Google Scholar

14. Ibrahimi A, Teboul L, Gaillard D, Amri EZ, Ailhaud G, Young P, et al. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in pre-adipose cells. Mol Pharmacol 1994;46:1070–6.Suche in Google Scholar

15. Kletzien RF, Clarke SD, Ulrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 1992;41:393–8.Suche in Google Scholar

16. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator activated receptor gamma (PPAR gamma). J Biol Chem 1995;270:12953–6.10.1074/jbc.270.22.12953Suche in Google Scholar PubMed

17. Komers R, Vrana A. Thiazolidinediones—tools for the research of metabolic syndrome X. Physiol Res 1998;47:215–25.Suche in Google Scholar

18. Evans RM, Barish GD, Wang Y-X. PPARs and the complex journey to obesity. Nat Med 2004;10:355–61.10.1038/nm1025Suche in Google Scholar

19. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43: 527–50.10.1021/jm990554gSuche in Google Scholar

20. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409–35.10.1146/annurev.med.53.082901.104018Suche in Google Scholar

21. Hansch C, Leo A. Substituent constants for correlation analysis in chemistry and biology. New York: John Wiley & Sons, 1979.Suche in Google Scholar

22. Rathi L, Kashaw SK, Dixit A, Pandey G, Saxena AK. Pharmacophore identification and 3D-QSAR studies in N-(2-benzoyl phenyl)-l-tyrosines as PPAR gamma agonists. Bioorg Med Chem 2004;12:63–9.10.1016/j.bmc.2003.10.032Suche in Google Scholar

23. Liao C, Xie A, Shi L, Zhou J, Lu X. Eigenvalue analysis of peroxisome proliferator-activated receptor gamma agonists. J Chem Inf Comput Sci 2004;44:230–8.10.1021/ci034109cSuche in Google Scholar

24. Hyun KH, Lee DY, Lee B, Kim CK. Receptor-based 3D QSAR studies on PPARgamma agonists using CoMFA and CoMSIA approaches. QSAR Comb Sci 2004;23:637–49.10.1002/qsar.200430878Suche in Google Scholar

25. Kurogi Y. Three-dimensional quantitative structure-activity relationships (3D-QSAR) of antidiabetic thiazolidinediones. Drug Des Discov 1999;16:109–18.Suche in Google Scholar

26. Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ, et al. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009;60:2822–9.10.1002/art.24761Suche in Google Scholar

27. Rucker C, Scarsi M, Meringer M. 2D QSAR of PPARgamma agonist binding and transactivation. Bioorg Med Chem 2006;14:5178–95.10.1016/j.bmc.2006.04.005Suche in Google Scholar

28. Kulkarni SS, Gediya LK, Kulkarni VM. Three-dimensional quantitative structure activity relationships (3-D-QSAR) of antihyperglycemic agents. Bioorg Med Chem 1999;7:1475–85.10.1016/S0968-0896(99)00063-2Suche in Google Scholar

29. Sotriffer CA, Winger RH, Liedl KR, Rode Bernd M, Varga JM. Comparative docking studies on ligand binding to the multispecific antibodies IgE-La2 and IgE-Lb4. J Comput Aided Mol Des 1996;10:305–20.10.1007/BF00124500Suche in Google Scholar PubMed

30. Brass LF. Thrombin and platelet activation. Chest 2003;124:3(Suppl):18S–25S.10.1378/chest.124.3_suppl.18SSuche in Google Scholar

31. Rubenstein LA, Lanzara RG. Activation of G protein-coupled receptors entails cysteine modulation of agonist binding. J Mol Struct (Theochem) 1998;430:57–71.10.1016/S0166-1280(98)90217-2Suche in Google Scholar

32. Raymond V, Sattelle DB. Novel animal-health drug targets from ligand-gated chloride channels. Nat Rev Drug Discov 2002;1:427–36.10.1038/nrd821Suche in Google Scholar

33. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008;21:659–67.10.1097/QCO.0b013e328318978fSuche in Google Scholar

34. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotech 2011;29:1039–45.10.1038/nbt.2017Suche in Google Scholar

35. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotech 2011;29:1046–51.10.1038/nbt.1990Suche in Google Scholar

36. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engström O, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753–8.10.1038/39645Suche in Google Scholar

37. Tenson T, Lovmar M, Ehrenberg M. The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol 2003;330:1005–14.10.1016/S0022-2836(03)00662-4Suche in Google Scholar

38. Katz AH, Caufield CE. Structure-based design approaches to cell wall biosynthesis inhibitors. Current Pharm Des 2003;9:857–66.10.2174/1381612033455305Suche in Google Scholar PubMed